Bayesian regression models for cost-effectiveness analysis

European Journal of Health Economics

Volumn 6, Issue 1, 2005, Pages 45-52

  Polo, Francisco José Vázquez ^a   Negrín, Miguel ^a   Badía, Xavier ^b   Roset, Montse ^b  

^a UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

^b Health Outcomes Research Europe   (Spain)

Author keywords

Bayesian analysis; Cost effectiveness; Discrete models; EQ 5D; Gibbs sampling

Indexed keywords

DIDANOSINE; INDINAVIR; LAMIVUDINE; STAVUDINE;

ARTICLE; BAYES THEOREM; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL MODEL; MEDICAL RECORD; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BAYES THEOREM; COST-BENEFIT ANALYSIS; HIV INFECTIONS; HUMANS;

EID: 17444381928     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-004-0256-z     Document Type: Article

References (39)

1. Spiegelhalter DJ, Freedman LS, Parmar MKB (1994) Bayesian approaches to randomized trials. J R Stat Soc A 157:357-416
2. Briggs AH (1999) A Bayesian approach to stochastic cost-effectiveness analysis. Health Econ 8:257-261
3. Briggs AH (2002) A Bayesian approach to stochastic cost-effectiveness analysis. An illustration and application to blood pressure control in type 2 diabetes. Int J Technol Assess Health Care 17:69-82
4. Heitjan DF, Moskowitz AJ, William W (1998) Bayesian estimation of cost-effectiveness ratios from clinical trials. Health Econ 8:191-201
5. O'Hagan A, Stevens JW, Montmartin J (2001) Bayesian cost-effectiveness analysis from clinical trial data. Stat Med 20:733-753
6. O'Hagan A, Stevens JW (2001) A framework for cost-effectiveness analysis from clinical trial data. Health Econ 10:303-315
7. Claxton K, Lacey LF, Walker SG (2000) Selecting treatments: a decision theoretic approach. J R Stat Soc A 163:211-225
8. Claxton K, Neumann PJ, Araki S, Weinstein M (2001) Bayesian value of information analysis. An application to a policy model of Alzheimer's disease. Int J Technol Assess Health Care 17:38-55
9. Claxton K (1999) Bayesian approaches to the value of information: implications for the regulation of new pharmaceuticals. Health Econ 8:269-274
10. Stevens JW, O'Hagan A (2001) Bayesian methods for cost-effectiveness analysis. Inter Soc Pharmacoecon Outcomes News 7
11. Kathleen E, Miller V, Ernst C, Nishimura K, Melvin C, Merritt R (2002) Neonatal health care costs related to smoking during pregnancy. Health Econ 11:193-206
12. Willan A, O'Brien B (2001) Cost prediction models for the comparison of two groups. Health Econ 10:363-366
13. O'Neill C, Groom L, Avery A, Boot D, Thornhill K (2000) Age and proximity to death as predictors of GP care costs: results from a study of nursing home patients. Health Econ 9:733-738
14. Healey A, Mirandola M, Amaddeo F, Bonizzato P, Tansella M (2000) Using health production functions to evaluate treatment effectiveness: an application to a community mental health service. Health Econ 9:373-383
15. Kronborg C, Andersen K, Kragh-Sorensen P (2000) Cost function estimation: the choice of a model to apply to dementia. Health Econ 9:397-409
16. Russell LB, Sisk JE (2000) Modelling age differences in cost-effectiveness analysis. A review of the literature. Int J Technol Assess Health Care 16:1158-1167
17. Hoch JS, Briggs AH, Willan A (2002) Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ 11:415-430
18. Willan AR, Briggs AH, Hoch JS (2004) Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. Health Econ 13:461-475
19. Mullahy J, Manning W (1994) Statistical issues of cost-effectiveness analysis. In Sloan F (ed) Value health care, vol 3. Cambridge University Press: Cambridge, 149-184
20. Van Hout BA, Al MJ, Gordon GS, Rutten FFH (1994) Costs, effects and C/E ratios alongside a clinical trial. Health Econ 3:309-319
21. Löthgren M, Zethraeus N (2000) Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ 9:623-630
22. Al MJ, Van Hout BA (2000) A Bayesian approach to economic analyses of clinical trials: the case of stenting versus balloon angioplasty. Health Econ 9:599-609
23. Fenwick E, Claxton K, Sculpher M (2001) Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 10:779-787
24. Pinto JL, López C, Badía X et al (2000) Análisis coste-efectividad del tratamiento antirretroviral de gran actividad en pacientes infectados por el VIH asintomáticos. Med Clin (Barc) 114:62-67
25. Brooks R with the EuroQol Group (1996) EuroQol the current state of play. Health Policy 37:53-72
26. Matthews JN, Altman DG, Campbell MJ, Royston P (1999) Analysis of serial measurements in medical research. BMJ 300 230-235
27. Mellors JW, Kingsley LA, Rinaldo CR Jr, Todd JA, Hoo BS, Kokka RP, Gupta P (1995) Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 122:573-579
28. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P et al (1997) Plasma viral load and CD4+lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126:946-954
29. Carpenter C, Fischl M, Hammer S, Hirsh M, Jacobsen D, Katzenstein D et al (1998) Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society - USA Panel. JAMA 280:78-86
30. Soriano V, De Mendoza C, Pérez-Olmeda M, González-Lahoz J (1998) Intensification therapy for patients achieving partial viral load suppression under antiretroviral therapy. Antiviral Ther 3:50-51
31. George E, McCulloch R (1993) Variable selection via Gibbs sampling. J Am Stat Assoc 88:881-889
32. Tweedie RL (1998) Markov chains: structure and applications. Technical report. Department of Statistics, Colorado State University
33. Gilks WR, Richardson S, Spiegelhalter DJ (1996) Markov chain Monte Carlo in practice. Chapman & Hall: London
34. Chaloner K, Rhame FS (2001) Quantifying and documenting prior beliefs in clinical trials. Stat Med 20:581-600
35. Wolpert RL (1989) Eliciting and combining subjective judgements about uncertainty. Int J Technol Assess Health Care 5:537-557
36. Kadane JB, Wolfson LJ (1998) Experiences in elicitation. J R Stat Soc D 47:3-19
37. Chaloner K (1995) The elicitation of prior distributions, in case studies in Bayesian biostatistics. Berry D, Stangl D (eds), Dekker: New York, 141-156
38. Griffiths WE, Carter R, O'Donnell CJ (2001) Including prior information in probit model estimation. Research paper no. 816. Department of Economics. University of Melbourne
39. Stevenes JW, O'Hagan A, Miller P (2003) Case study in the Bayesian analysis of a cost-effectiveness trial in the evaluation of health care technologies: depression. Pharm Stat 2:51-68